November 11, 1:24 PM
HOOKIPA Pharma (NASDAQ:HOOK) has observed the following analyst ratings within the last quarter:
November 11, 7:24 AM
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from $21 to $15.
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 9:19 AM
Here's a roundup of top developments in the biotech space over the last 24 hours.
November 10, 8:44 AM
JMP Securities analyst Jason Butler maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Market Outperform and lowers the price target from $25 to $11.
November 10, 7:31 AM
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 15.09 percent decrease over losses of $(0.53) per share from
HOOKIPA Advances HB-200 Program To Phase 2 And Prioritizes Oncology Portfolio Based On Clinical Data Updates Across Its Novel Arenaviral Platform
November 9, 5:35 PM
Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st and 2nd line head and neck cancer Interim Phase 1 HB-200 data